Filing summary
Entity mismatch: Although the request identifies Humacyte, Inc., the supplied filing is Alpha Healthcare Acquisition Corp.’s Form 10-Q. It does not report Humacyte’s results.
Business context and reporting period
The filing covers the period from July 1, 2020 (inception) through September 30, 2020. Alpha Healthcare Acquisition Corp. was a newly formed, healthcare-focused blank-check company seeking a U.S. healthcare business combination. It had not selected a target or begun substantive discussions with one and had not commenced operations. Its IPO closed September 22, 2020.
Financial results, liquidity, and obligations
- Revenue: No operating revenue; the company said it would not generate operating revenue before completing a business combination.
- Loss: Net loss was $40,952, comprising $18,775 of formation and operating costs and a $22,177 unrealized loss on trust-account securities. Basic and diluted loss per share was $0.01.
- Cash flow: Operating cash use was $18,049; investing cash use was $100.0 million, reflecting the trust-account deposit; financing cash provided was $101.3 million. Ending cash outside the trust was $1.316 million.
- Assets and liquidity: Total assets were $101.325 million, including $99.978 million of trust-account securities. The $100.0 million trust balance was generally unavailable before a business combination, except as provided for redemptions and permitted tax withdrawals. Management expected outside-trust cash to fund operations for at least 12 months, assuming no business combination during that time.
- Liabilities and equity: Total liabilities were $1.967 million, including $89,076 due under a non-interest-bearing sponsor promissory note and a $1.846 million deferred underwriting fee payable upon a completed business combination. Stockholders’ equity was $5.000 million; $94.358 million of Class A shares was classified as temporary equity subject to possible redemption.
- Capital raised: The IPO raised $100.0 million gross and a private placement raised $3.55 million gross. Transaction costs were $4.176 million. The company reported no long-term debt or off-balance-sheet arrangements.
Changes, outlook, and risks
No prior comparable-period results are provided because the company was formed on July 1, 2020. The 45-day underwriters’ over-allotment option was not exercised; 375,000 founder shares were consequently forfeited on November 1, 2020, after quarter-end.
The company had 24 months from the IPO closing to complete a business combination, subject to possible extension with stockholder approval. If it failed, it would redeem public shares from the trust and liquidate. Public stockholders could redeem shares in connection with a completed transaction. Management cautioned that additional funding might be needed if diligence and transaction costs exceed estimates; sponsor, officer, and director loans were optional, not committed. COVID-19 could hinder the search or transaction process, but its specific financial impact was not determinable.
Other notable terms include a target-business fair-market-value test of at least 80% of the trust balance, net of taxes, when an agreement is signed; potential dilution from transaction financing and founder-share conversion provisions; and sponsor indemnification for certain third-party claims against the trust, which the company said it could not assure the sponsor could meet. The filing reported no legal proceedings and no material changes to previously disclosed risk factors. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Investor verification points
- Confirm the intended filing: this document is Alpha Healthcare Acquisition Corp.’s filing, not a Humacyte, Inc. filing.
- Verify the status of the business-combination search and the remaining time before the 24-month deadline.
- Track trust assets, redemption levels, and cash available outside the trust for operating and transaction costs.
- Review potential dilution, founder-share conversion, warrants, and the deferred underwriting fee when assessing a proposed transaction.
- Assess whether sponsor indemnification or optional working-capital financing would be available and sufficient if needed.